Arming the patient's immune system to fight cancer

2015 Q4 Presentation

March 2, 2016

Important notice and disclaimer

- This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

- There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Targovax's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.

“Arming the patient’s immune system to fight cancer”

1 An emerging immuno-oncology leader

- ✓ Oncolytic adenoviruses targeted at all solid, injectable tumors
- ✓ RAS-mutated peptide immunotherapy, targeted at all RAS-mutated cancers

2 Unique portfolio with promising data

- ✓ ONCOS-102 is the only oncolytic virus which has shown tumor-specific T-cell activation
- ✓ TG01 is the only RAS-specific cancer vaccine in development

ONCOS

TG

3 Multiple value inflection points

- ✓ Multiple shots on goal through programs in 6 indications
- ✓ 8 clinical read-outs over next 2 years

4 Experienced management team

- ✓ A highly experienced international management team
- ✓ Strong and recently strengthened board

5 Backed by leading life science investors

- ✓ Private placement of NOKm 200 (USDm 25) in June 2015
- ✓ HealthCap is the largest owner with 31.6 %
- ✓ IPO planned for 2016

Cash highlights Q4 2015

Cash and cash equivalents (NOKm)



- IPO planned for 2016
- Current cash with current plans lasts towards the end of 2016
- Targovax has retained flexibility to in its cost structure, enabling the cash position to last into early 2017

P&L Overview

NOKm	4Q14	1Q15	2Q15	3Q15	4Q15	FY2014	FY 2015
Total revenue	**0**	**-**	**-**	**0**	**0**	**-**	**0**
Cost of manufacturing for R&D	-5	-0	-2	-3	-3	-6	-9
Payroll and related expenses	-3	-3	-4	-13	-15	-5	-35
Depreciation	-0	-0	-0	-0	-0	-0	-0
Other operating expenses	-1	-3	-7	-13	-22	-6	-45
Total operating expenses	**-8**	**-7**	**-13**	**-29**	**-41**	**-18**	**-90**
Operating loss	**-8**	**-7**	**-13**	**-29**	**-41**	**-18**	**-90**
Financial income	0	0	0	2	0	0	2
Financial expenses	-0	-0	-0	-1	-1	-0	-3
Net financial items	**0**	**-0**	**0**	**1**	**-1**	**-0**	**-0**
Loss before income tax	**-8**	**-7**	**-13**	**-29**	**-42**	**-18**	**-90**

Q4 2015 – progressing according to plan

- ✓ Announced an agreement with Ludwig Cancer Research (LICR) and the Cancer Research Institute (CRI) in New York to evaluate ONCOS-102 in combination with other immunotherapies such as checkpoint inhibitors
- ✓ Entered into an agreement with the biotech company Sotio to run a collaboration study combining ONCOS-102 and Sotio's dendritic cell therapy to evaluate the safety and tolerability in the treatment of advanced prostate cancer
- ✓ Progressed the preparation of three new combination clinical trials according to plan
- ✓ Presented promising immune biomarker data from a phase I study with ONCOS-102 at the SITC (Society for Immunotherapy of Cancer) conference in Washington DC in November
- ✓ Increased investor relations efforts in the US and Nordics
- ✓ Participated at JPMorgan's Healthcare Conference in San Francisco, DNB's Healthcare conference in Oslo, Arctic's biotech seminar in Oslo and Redeye's Immuno-oncology event in Stockholm

Expected news flow 2016 – 2018 shows multiple value inflection points



Targovax focus on: Solid tumors susceptible to immunotherapy and those with RAS mutations

ONCOS: Solid tumors

Tumor type	Response to CPIs
Melanoma	~50% / 50%
Triple Negative Breast	~70-80% / ~30-20%
Renal Cell Carcinoma	~70% / 30%
Lung Carcinoma (NSCLC)	~80% / 20%
Head and Neck	~80%[1] / 20%
Bladder	~84%[2] / 16%

Non-responders Responders

Most solid tumors do not respond to CPIs – combination therapies are needed

TG: RAS mutations



RAS mutations represent a unique target for immunotherapy – Pancreas and Colorectum suggested as first indications

[1] Patients were preselected by Merck PD-L1 IHC assay
[2] 11% in PD-L1 (Roche) negative: 43% in PD-L1 + population
[3] Cancer Res, PS 2012, Nov 15, 2012

Targovax has differentiated assets with orphan indications*



- Targovax has a broad and diversified pipeline with several promising compounds targeting multiple indications
- There is a low price tag of advancing the compounds to a go/no-go decision for the specific indications

Current view of the clinical development program 2016 – 2018



TG01 in Pancreatic Cancer – Study design



TG02 in Colorectal Cancer – Study design



ONCOS-102 in Malignant Melanoma – Study design



ONCOS-102 in Mesothelioma – Study design



Where are we with the clinical studies?

Resected pancreas	**Resected pancreas study with TG01 and chemotherapy**	○ 6 patients recruited into the modified cohort ○ Interim analysis (1 year OS in initial cohort, 8 week immune activation in first patients in modified cohort) on track for 2Q16
Mesothelioma	**Mesothelioma study with ONCOS-102 and chemotherapy**	○ Finalized and signed-off protocol in collaboration with investigators and external experts ○ Selected/contracted a CRO (contract research organization) ○ Selected 2 investigational sites in Spain ○ Submitted study documentation to Spanish regulatory authorities ○ On track to be site ready for recruitment in June
Colorectal	**Colorectal study with TG02 and check point inhibitor**	○ Finalized and signed off protocol in collaboration with investigators and external experts ○ Selected/contracted CRO ○ Selected 3 sites in Australia (with an option to open up further sites in New Zealand) ○ Submitted study documentation to the Australian External Review Body for early phase studies – approved December 2015 ○ Submitted to Ethics – ongoing ○ On track to be site ready for recruitment in June

Where are we with the clinical studies?

Melanoma	**Melanoma study with ONCOS-102 and check point inhibitor**	○ Protocol close to finalized ○ US site selected ○ On track to be site ready for recruitment in 2H16
Prostate	**Signed collaborative agreement with Sotio for a study of ONCOS-102 and DC/VAC in prostate cancer**	○ Protocol finalized and signed-off ○ Sites selected in Prague and Helsinki ○ Sotio will manage study/be the sponsor ○ Study documentation submitted to regulatory authorities in Prague and Helsinki – ongoing, long(er) review time as none of the two technologies have been commercialized ○ Study to start in 2H16
Peritoneal malignancies	**Signed collaborative agreement with Cancer Research Institute for a study of ONCOS-102 and a check point inhibitor in peritoneal malignancies**	○ Protocol finalized and signed-off ○ 2 lead sites in US selected ○ Ludwig Institute of Cancer Research will manage study/be the sponsor ○ Protocol now with large pharma company who will supply the check point inhibitor ○ On track to be site ready for recruitment 2H16

Unique immuno-oncology portfolio with promising data

1. Immuno-oncology is the fastest growing life science segment
2. Unique portfolio with promising phase I data
3. Multiple value inflection points
4. Experienced management team
5. Backed by leading life science investors